P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis

• Main Authors: Wen-Han Feng (Author), Yong-Chieh Chang (Author), Yi-Hsiung Lin (Author), Hsiao-Ling Chen (Author), Chun-Yin Chen (Author), Tsung-Han Lin (Author), Tzu-Chieh Lin (Author), Ching-Tang Chang (Author), Hsuan-Fu Kuo (Author), Hsiu-Mei Chang (Author), Chih-Sheng Chu (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it could lower the risk of bleeding complications without increased ischemic events as compared to standard dual antiplatelet...